[
  {
    "ts": "2025-12-04T05:05:00+00:00",
    "headline": "Jim Cramer on Pfizer: “I Would Hold on to It”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-pfizer-hold-050500313.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "bdf2d0a1-8b63-32a6-9e52-50badd7e1fac",
      "content": {
        "id": "bdf2d0a1-8b63-32a6-9e52-50badd7e1fac",
        "contentType": "STORY",
        "title": "Jim Cramer on Pfizer: “I Would Hold on to It”",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think […]",
        "pubDate": "2025-12-04T05:05:00Z",
        "displayTime": "2025-12-04T05:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lBNvOkwEcDTC6JSi8u6u5Q--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l4R272WQ4gg_U7DbC5QzrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-pfizer-hold-050500313.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-pfizer-hold-050500313.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T13:30:00+00:00",
    "headline": "Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview",
    "summary": "Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases. ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified",
    "url": "https://finance.yahoo.com/news/renowned-immunologist-urological-surgeon-dr-133000336.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "42ef5e3c-efae-3eac-a699-2095fe2acc0a",
      "content": {
        "id": "42ef5e3c-efae-3eac-a699-2095fe2acc0a",
        "contentType": "STORY",
        "title": "Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview",
        "description": "",
        "summary": "Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases. ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified",
        "pubDate": "2025-12-04T13:30:00Z",
        "displayTime": "2025-12-04T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/7395d76f3809bbf7c46acc0ab1afe500",
          "originalWidth": 1920,
          "originalHeight": 1080,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HR07QlTVHknrP.l7A.ZgfQ--~B/aD0xMDgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/7395d76f3809bbf7c46acc0ab1afe500.cf.webp",
              "width": 1920,
              "height": 1080,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tImub8OencN9kFV5z_99gw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7395d76f3809bbf7c46acc0ab1afe500.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/renowned-immunologist-urological-surgeon-dr-133000336.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/renowned-immunologist-urological-surgeon-dr-133000336.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LMMY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T16:03:00+00:00",
    "headline": "Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing",
    "summary": "The report highlights opportunities in pharmaceutical outsourcing through emerging trends, new contracts, M&A activities, and investments in technology. It guides CMOs, pharmaceutical decision-makers, and investors in strategic planning and supplier management by providing insights into regulatory impacts and supply chain developments.Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The \"Bio/Pharmaceutical Outsourcing Report, October 2025\" report has been added to ResearchAndMarkets.com's offering.The",
    "url": "https://finance.yahoo.com/news/bio-pharmaceutical-outsourcing-report-october-160300830.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "bfad300c-faac-3783-94c0-55822c88f123",
      "content": {
        "id": "bfad300c-faac-3783-94c0-55822c88f123",
        "contentType": "STORY",
        "title": "Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing",
        "description": "",
        "summary": "The report highlights opportunities in pharmaceutical outsourcing through emerging trends, new contracts, M&A activities, and investments in technology. It guides CMOs, pharmaceutical decision-makers, and investors in strategic planning and supplier management by providing insights into regulatory impacts and supply chain developments.Dublin, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The \"Bio/Pharmaceutical Outsourcing Report, October 2025\" report has been added to ResearchAndMarkets.com's offering.The",
        "pubDate": "2025-12-04T16:03:00Z",
        "displayTime": "2025-12-04T16:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-pharmaceutical-outsourcing-report-october-160300830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-pharmaceutical-outsourcing-report-october-160300830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T14:27:00+00:00",
    "headline": "3 Large Drug Stocks to Watch as the Industry Shows Some Recovery",
    "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.",
    "url": "https://finance.yahoo.com/news/3-large-drug-stocks-watch-142700725.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "18569e85-7832-39f7-8e4b-10938849c2b4",
      "content": {
        "id": "18569e85-7832-39f7-8e4b-10938849c2b4",
        "contentType": "STORY",
        "title": "3 Large Drug Stocks to Watch as the Industry Shows Some Recovery",
        "description": "",
        "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.",
        "pubDate": "2025-12-04T14:27:00Z",
        "displayTime": "2025-12-04T14:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-large-drug-stocks-watch-142700725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-large-drug-stocks-watch-142700725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]